Summit Therapeutic SMMT 深 滬
等待開盤 12-18 09:30:00 美东时间
17.01
-0.220
-1.28%
華盛通- 最 高17.85
- 今 開17.65
- 成交量 268.29万股
- 最 低 16.99
- 昨 收 17.23
- 總市值 126.38亿
- 52周最高 36.91
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 15.55
- 委 比 75.22%
- 總股本 7.43亿
- 歷史最高 36.91
- 量 比 1.26
- 振 幅 4.99%
- 歷史最低 0.66
- 每 手 1
- 風險率 3.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
今天 10:54
Barclays Upgrades Summit Therapeutics to Equal-Weight, Raises Price Target to $18
Barclays analyst Etzer Darout upgrades Summit Therapeutics (NASDAQ:SMMT) from Underweight to Equal-Weight and raises the price target from $16 to $18.
12-17 22:45
Small Caps Rally, Natural Gas Prices Jump To 3-Year Highs: What's Moving Markets Wednesday?
Small-cap stocks powered higher Wednesday as expectations for a rate cut next week strengthened after weaker-than-expected private employment data. The Russell 2000 climbed more than 1% by midday in New York, lifted by rising odds of a 25-basis-point cut at the Fed's Dec. 10 meeting. The CME FedWatch tool shows a 90% chance of a move, with odds of another cut in January near 30%.
12-04 01:46
Wolfe Research Initiates Coverage On Summit Therapeutics with Peer Perform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Peer Perform rating.
11-19 01:14
Summit Therapeutics Partner Akeso Publishes Results From Phase III HARMONi-A Trial Showing Statistically Significant OS Benefit
The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing RegimenIvonescimab Plus Chemotherapy Demonstrates Median OS of 16.8 Months
11-07 22:10
美股夜盘 | Affirm涨10.73%，Innodata涨7.91%
Affirm涨10.73%；Innodata涨7.91%；PMGC Holdings Inc.涨4.06%
11-07 10:02
10.24商业观察：创新药出海龙头股汇总（附股）
（来源：华彬金融观察） 创新药再迎重磅利好催化。 信达生物宣布与武田制药达成全球战略合作，共同推进新一代免疫肿瘤（IO）及抗体药物偶联物（ADC）疗法开发，合作...
10-24 06:02
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
